Contrasting MaxCyte (NASDAQ:MXCT) and Maravai LifeSciences (NASDAQ:MRVI)

MaxCyte (NASDAQ:MXCT – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Profitability

This table compares MaxCyte and Maravai LifeSciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MaxCyte -81.40% -15.05% -12.79%
Maravai LifeSciences -30.83% -12.44% -6.66%

Insider and Institutional Ownership

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 50.2% of Maravai LifeSciences shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares MaxCyte and Maravai LifeSciences”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MaxCyte $33.03 million 3.83 -$44.63 million ($0.26) -4.72
Maravai LifeSciences $185.74 million 10.27 -$130.77 million ($0.43) -17.07

MaxCyte has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MaxCyte has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for MaxCyte and Maravai LifeSciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte 1 1 1 0 2.00
Maravai LifeSciences 1 1 3 1 2.67

MaxCyte currently has a consensus target price of $4.50, suggesting a potential upside of 267.05%. Maravai LifeSciences has a consensus target price of $8.10, suggesting a potential upside of 10.35%. Given MaxCyte’s higher probable upside, equities research analysts plainly believe MaxCyte is more favorable than Maravai LifeSciences.

Summary

Maravai LifeSciences beats MaxCyte on 8 of the 15 factors compared between the two stocks.

About MaxCyte

(Get Free Report)

MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.